Short answer
Vir Biotechnology, Inc. (VIR) filed an 8-K current report with the SEC on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 financial results for quarter ended June 30, 2026.
Vir Biotechnology, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results for quarter ended June 30, 2026
- Press release furnished as Exhibit 99.1 contains the detailed results
- Filing provides no financial figures beyond the reporting period
Item EX-99.1 · Exhibit EX-99.1
- SOLSTICE Week 96: undetectable HDV RNA in 88% combination-treated participants versus 53% on monotherapy
- ECLIPSE 1 topline data expected Q4 2026, making the next major CHD catalyst regulatory-relevant
- Astellas collaboration delivered $240.0M upfront and $75M equity investment, supporting cash of $1.01B and runway into H2 2028
- Q2 revenue $238.9M and net income $80.1M, or $0.48 diluted EPS, primarily from Astellas upfront-payment recognition
- VIR-5500 prostate-cancer dose expansions initiated, with pivotal Phase 3 trials anticipated in 2027
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Vir Biotechnology, Inc. 8-K filings
Get the next VIR 8-K as it lands
Follow VIR for push alerts, or ask the research agent what this filing means.